首页 > 最新文献

Communicable diseases intelligence (2018)最新文献

英文 中文
Public health rapid response in managing COVID-19 outbreaks in residential aged care facilities: a regional public health unit perspective. 从地区公共卫生单位的角度看公共卫生快速反应在管理安老院COVID-19爆发中的作用。
Q3 Medicine Pub Date : 2024-10-23 DOI: 10.33321/cdi.2024.48.36
Mohammad Rashidul Hashan, Jacina Walker, Margaret Charles, Susie Le Brasse, Danielle Odorico, Nicolas Smoll, Michael Kirk, Robert Booy, Gulam Khandaker

Abstract: We describe here the impact of managing coronavirus disease 2019 (COVID-19) outbreaks, during January-August 2022, in residential aged care facilities (RACFs) in Central Queensland, Australia, following the deployment of a public health rapid response team (PHRRT, comprising a medical officer, a communicable disease nurse, and an epidemiologist) from a regional public health unit (PHU). Our existing vaccine preventable diseases surveillance framework was used in identifying any symptomatic resident, triggering a PHRRT response. We found that the Hospital in the Home (HiTH) admission and death events were significantly lower after the introduction of the PHRRT than in the outbreaks that occurred before. Based on our experience with a PHRRT-led approach in mitigating the burden of outbreaks, we recommend regular reflection on optimising resources and practices in RACFs. Effective communication from PHUs can improve the RACFs' preparedness and capacity to respond, and can inform the best practice model to protect the highly susceptible elderly residents and their staff.

摘要:我们在此描述了 2022 年 1 月至 8 月期间,在澳大利亚昆士兰州中部的养老院 (RACF) 中爆发冠状病毒病 2019 (COVID-19) 后,地区公共卫生单位 (PHU) 派出公共卫生快速反应小组 (PHRRT,由一名医务人员、一名传染病护士和一名流行病学家组成) 进行管理所产生的影响。我们现有的疫苗可预防疾病监测框架用于识别任何有症状的居民,并触发 PHRRT 响应。我们发现,引入 PHRRT 后,居家医院(HiTH)的入院率和死亡事件明显低于之前的爆发。根据我们在 PHRRT 领导下减轻疫情爆发负担的经验,我们建议定期反思如何优化区域活动中心的资源和做法。来自公共卫生单位的有效沟通可提高区域活动中心的准备程度和应对能力,并可为最佳实践模式提供信息,以保护极易感染疫情的长者住户及其员工。
{"title":"Public health rapid response in managing COVID-19 outbreaks in residential aged care facilities: a regional public health unit perspective.","authors":"Mohammad Rashidul Hashan, Jacina Walker, Margaret Charles, Susie Le Brasse, Danielle Odorico, Nicolas Smoll, Michael Kirk, Robert Booy, Gulam Khandaker","doi":"10.33321/cdi.2024.48.36","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.36","url":null,"abstract":"<p><strong>Abstract: </strong>We describe here the impact of managing coronavirus disease 2019 (COVID-19) outbreaks, during January-August 2022, in residential aged care facilities (RACFs) in Central Queensland, Australia, following the deployment of a public health rapid response team (PHRRT, comprising a medical officer, a communicable disease nurse, and an epidemiologist) from a regional public health unit (PHU). Our existing vaccine preventable diseases surveillance framework was used in identifying any symptomatic resident, triggering a PHRRT response. We found that the Hospital in the Home (HiTH) admission and death events were significantly lower after the introduction of the PHRRT than in the outbreaks that occurred before. Based on our experience with a PHRRT-led approach in mitigating the burden of outbreaks, we recommend regular reflection on optimising resources and practices in RACFs. Effective communication from PHUs can improve the RACFs' preparedness and capacity to respond, and can inform the best practice model to protect the highly susceptible elderly residents and their staff.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of a risk stratification tool for SARS-CoV-2 Delta community transmission in the Australian Capital Territory. 验证澳大利亚首都地区 SARS-CoV-2 三角洲社区传播的风险分层工具。
Q3 Medicine Pub Date : 2024-10-23 DOI: 10.33321/cdi.2024.48.40
Alexandra Marmor, Tze Vun Voo, Meru Sheel, Timothy Sloan-Gardner, Nevada Pingault

Abstract: During the SARS-CoV-2 Delta (B.1.617.2) variant outbreak, from August to October 2021 in the Australian Capital Territory (ACT), the number of new cases 'in the community for part of their infectious period' was publicly reported daily. We describe the stratification tool used during the outbreak to determine presumptive risk of community transmission from cases, and present the results of a contemporaneous validation of each case's risk against their onward transmission detected by routine surveillance. After case interview, epidemiologists identified the most likely source of infection for each new case and used the stratification tool to classify the case as either no, low, or high risk of community transmission. Each case notified between 12 August and 14 September 2021 was matched to its recipient case(s) to determine how well the tool predicted transmission risk. Household transmissions were excluded. Of the 530 notified cases stratified, 159 (29.3%) were cases who transmitted to a recipient case. Of the 59 cases who were the source of community transmission, 66% (38/59) were undertaking high-risk activities not associated with permitted essential work at the time. Only six source cases stratified as low risk or no risk transmitted SARS-CoV-2 to those outside their own household. The tool was essential in the rapid determination of community transmission risk in the ACT, and validation of the tool against detected onward transmission provided evidence for the effectiveness of public health restrictions. In the early stages of outbreaks of diseases for which transmissibility has not yet been established, the validation of such a stratification tool relies on high quality case investigation data, but may help to understand transmission dynamics and to inform interventions.

摘要:2021年8月至10月,澳大利亚首都地区(ACT)爆发了SARS-CoV-2 Delta (B.1.617.2)变异体疫情,在此期间,每天都会公开报告 "部分感染期在社区内 "的新病例数量。我们描述了疫情爆发期间用于确定病例社区传播推定风险的分层工具,并介绍了根据常规监测发现的病例继续传播情况对每个病例的风险进行同期验证的结果。在对病例进行访谈后,流行病学专家确定了每个新病例最可能的感染源,并使用分层工具将病例划分为无社区传播风险、低社区传播风险或高社区传播风险。2021 年 8 月 12 日至 9 月 14 日期间通报的每个病例都与接收病例进行了比对,以确定该工具预测传播风险的准确性。家庭传播被排除在外。在分层的 530 个通报病例中,有 159 个病例(29.3%)传播给了接收病例。在 59 个社区传播源病例中,66%(38/59)当时正在从事与获准的基本工作无关的高风险活动。只有 6 个被分层为低风险或无风险的源头病例将 SARS-CoV-2 传染给了自己家庭以外的人。该工具对于快速确定澳大利亚首都地区的社区传播风险至关重要,而根据检测到的继续传播情况对该工具进行验证则为公共卫生限制措施的有效性提供了证据。在传播性尚未确定的疾病爆发的早期阶段,这种分层工具的验证依赖于高质量的病例调查数据,但可能有助于了解传播动态并为干预措施提供信息。
{"title":"Validation of a risk stratification tool for SARS-CoV-2 Delta community transmission in the Australian Capital Territory.","authors":"Alexandra Marmor, Tze Vun Voo, Meru Sheel, Timothy Sloan-Gardner, Nevada Pingault","doi":"10.33321/cdi.2024.48.40","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.40","url":null,"abstract":"<p><strong>Abstract: </strong>During the SARS-CoV-2 Delta (B.1.617.2) variant outbreak, from August to October 2021 in the Australian Capital Territory (ACT), the number of new cases 'in the community for part of their infectious period' was publicly reported daily. We describe the stratification tool used during the outbreak to determine presumptive risk of community transmission from cases, and present the results of a contemporaneous validation of each case's risk against their onward transmission detected by routine surveillance. After case interview, epidemiologists identified the most likely source of infection for each new case and used the stratification tool to classify the case as either no, low, or high risk of community transmission. Each case notified between 12 August and 14 September 2021 was matched to its recipient case(s) to determine how well the tool predicted transmission risk. Household transmissions were excluded. Of the 530 notified cases stratified, 159 (29.3%) were cases who transmitted to a recipient case. Of the 59 cases who were the source of community transmission, 66% (38/59) were undertaking high-risk activities not associated with permitted essential work at the time. Only six source cases stratified as low risk or no risk transmitted SARS-CoV-2 to those outside their own household. The tool was essential in the rapid determination of community transmission risk in the ACT, and validation of the tool against detected onward transmission provided evidence for the effectiveness of public health restrictions. In the early stages of outbreaks of diseases for which transmissibility has not yet been established, the validation of such a stratification tool relies on high quality case investigation data, but may help to understand transmission dynamics and to inform interventions.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mycoplasma genitalium retrospective audit of Northern Territory isolates from 2022. 对 2022 年北部地区分离的生殖器支原体进行回顾性审计。
Q3 Medicine Pub Date : 2024-08-21 DOI: 10.33321/cdi.2024.48.43
Kate E Proudmore, Manoji Gunathilake, Lucy C Crawford, Kevin Freeman, Dimitrios Menouhos, Rob W Baird

Abstract: The Northern Territory (NT) has the highest rates of sexually transmitted infections (STI) in Australia; however, the local prevalence of Mycoplasma genitalium (M. genitalium) has not been previously determined. This study was designed to review M. genitalium detection, to determine the regional NT prevalence and macrolide resistance rates. In our study the NT background prevalence of M. genitalium is 13%, with the highest detection rates occurring in central Australia and in correctional facility inmates. Symptomatic patients attending sexual health clinics have a positivity rate of 12%, but very high macrolide resistance. The decision to screen for M. genitalium should be based on several factors, including the prevalence of the infection in the local population; the availability of effective treatments; and the potential benefits and risks of detection and therapy.

摘要:北领地(NT)是澳大利亚性传播感染(STI)发病率最高的地区;然而,当地生殖支原体(M. genitalium)的发病率此前尚未确定。本研究旨在审查生殖器支原体的检测情况,确定北部地区的流行率和大环内酯类药物的耐药率。在我们的研究中,北部地区 M. 生殖器桿菌的背景流行率为 13%,澳大利亚中部和惩教机构囚犯中的检出率最高。到性健康诊所就诊的无症状患者的阳性率为 12%,但对大环内酯类药物的耐药性非常高。筛查 M. 生殖器畸形的决定应基于多个因素,包括当地人口的感染率、有效治疗方法的可用性,以及检测和治疗的潜在益处和风险。
{"title":"Mycoplasma genitalium retrospective audit of Northern Territory isolates from 2022.","authors":"Kate E Proudmore, Manoji Gunathilake, Lucy C Crawford, Kevin Freeman, Dimitrios Menouhos, Rob W Baird","doi":"10.33321/cdi.2024.48.43","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.43","url":null,"abstract":"<p><strong>Abstract: </strong>The Northern Territory (NT) has the highest rates of sexually transmitted infections (STI) in Australia; however, the local prevalence of <i>Mycoplasma genitalium</i> (<i>M. genitalium</i>) has not been previously determined. This study was designed to review <i>M. genitalium</i> detection, to determine the regional NT prevalence and macrolide resistance rates. In our study the NT background prevalence of <i>M. genitalium</i> is 13%, with the highest detection rates occurring in central Australia and in correctional facility inmates. Symptomatic patients attending sexual health clinics have a positivity rate of 12%, but very high macrolide resistance. The decision to screen for <i>M. genitalium</i> should be based on several factors, including the prevalence of the infection in the local population; the availability of effective treatments; and the potential benefits and risks of detection and therapy.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of age, January 2020 - December 2021. 澳大利亚抗菌药物研究小组监测结果计划--2020 年 1 月至 2021 年 12 月 18 岁以下患者的血液感染和抗菌药物耐药性模式。
Q3 Medicine Pub Date : 2024-08-21 DOI: 10.33321/cdi.2024.48.32
Anita Williams, Geoffrey W Coombs, Jan Bell, Denise A Daley, Shakeel Mowlaboccus, Penelope A Bryant, Anita J Campbell, Louise Cooley, Jon Iredell, Adam D Irwin, Alison Kesson, Brendan McMullan, Morgyn S Warner, Phoebe Williams, Christoper C Blyth

Abstract: From 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates. Overall, there were 902 gram-negative isolates reported: 800 Enterobacterales, 61 Pseudomonas aeruginosa and 41 Acinetobacter spp. Among the Enterobacterales, 12.9% were resistant to third generation cephalosporins; 11.6% to gentamicin/tobramycin; and 11.2% to piperacillin-tazobactam. In total, 14.5% of Enterobacterales were multi-drug resistant (MDR). Only 3.3% of P. aeruginosa were resistant to carbapenems and 4.9% were MDR. Resistance in Acinetobacter spp was uncommon. Of 607 Staphylococcus aureus isolates, 12.9% were methicillin-resistant (MRSA). Almost half of S. aureus isolates from the Northern Territory were MRSA. In S. aureus, resistance to erythromycin was 13.2%; 12.4% to clindamycin; and 5.3% to ciprofloxacin. Resistance to all antibiotics tested was higher in MRSA. Overall, 6.5% of S. aureus were MDR, of which 65% were MRSA. Almost three-quarters of the 170 Enterococcus spp. reported were E. faecalis, and half were from patients < 1 year old. Ampicillin resistance in enterococci was 19.6%. Eight isolates were vancomycin resistant and three isolates were teicoplanin resistant. Five E. faecium isolates were classified as MDR. This AGAR-Kids report highlights clear differences in the geographic distribution of pathogens and resistance profiles across Australia.

摘要:从2020年1月1日至2021年12月31日,澳大利亚有38家机构向澳大利亚抗菌药耐药性小组(AGAR)提交了小于18岁患者的数据(AGAR-Kids)。在这两年中,共报告了来自 1611 名患者的 1679 份分离物。这份 AGAR-Kids 报告旨在描述向 AGAR 报告菌血症的儿童和青少年群体以及耐药分离菌的比例。总体而言,共报告了 902 例革兰阴性菌分离株:在肠杆菌中,12.9%对第三代头孢菌素耐药;11.6%对庆大霉素/妥布霉素耐药;11.2%对哌拉西林-他唑巴坦耐药。总共有 14.5%的肠杆菌具有多重耐药性(MDR)。只有 3.3% 的铜绿假单胞菌对碳青霉烯类产生耐药性,4.9% 的铜绿假单胞菌对 MDR 产生耐药性。不动杆菌属的耐药性并不常见。在分离出的 607 株金黄色葡萄球菌中,12.9% 对甲氧西林(MRSA)具有耐药性。在北部地区分离出的金黄色葡萄球菌中,几乎有一半是 MRSA。金黄色葡萄球菌对红霉素的耐药性为 13.2%,对克林霉素的耐药性为 12.4%,对环丙沙星的耐药性为 5.3%。MRSA 对所有测试抗生素的耐药性都较高。总体而言,6.5%的金黄色葡萄球菌具有 MDR,其中 65% 为 MRSA。在报告的 170 种肠球菌中,近四分之三为粪肠球菌,其中一半来自年龄小于 1 岁的患者。肠球菌对氨苄西林的耐药性为 19.6%。8 个分离株对万古霉素耐药,3 个分离株对替考拉宁耐药。5 个粪肠球菌分离物被归类为 MDR。这份 AGAR-Kids 报告强调了澳大利亚各地病原体地理分布和耐药性概况的明显差异。
{"title":"Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of age, January 2020 - December 2021.","authors":"Anita Williams, Geoffrey W Coombs, Jan Bell, Denise A Daley, Shakeel Mowlaboccus, Penelope A Bryant, Anita J Campbell, Louise Cooley, Jon Iredell, Adam D Irwin, Alison Kesson, Brendan McMullan, Morgyn S Warner, Phoebe Williams, Christoper C Blyth","doi":"10.33321/cdi.2024.48.32","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.32","url":null,"abstract":"<p><strong>Abstract: </strong>From 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates. Overall, there were 902 gram-negative isolates reported: 800 <i>Enterobacterales</i>, 61 <i>Pseudomonas aeruginosa</i> and 41 <i>Acinetobacter</i> spp. Among the <i>Enterobacterales</i>, 12.9% were resistant to third generation cephalosporins; 11.6% to gentamicin/tobramycin; and 11.2% to piperacillin-tazobactam. In total, 14.5% of <i>Enterobacterales</i> were multi-drug resistant (MDR). Only 3.3% of <i>P. aeruginosa</i> were resistant to carbapenems and 4.9% were MDR. Resistance in <i>Acinetobacter</i> spp was uncommon. Of 607 <i>Staphylococcus aureus</i> isolates, 12.9% were methicillin-resistant (MRSA). Almost half of <i>S. aureus</i> isolates from the Northern Territory were MRSA. In <i>S. aureus</i>, resistance to erythromycin was 13.2%; 12.4% to clindamycin; and 5.3% to ciprofloxacin. Resistance to all antibiotics tested was higher in MRSA. Overall, 6.5% of <i>S. aureus</i> were MDR, of which 65% were MRSA. Almost three-quarters of the 170 <i>Enterococcus</i> spp. reported were <i>E. faecalis</i>, and half were from patients < 1 year old. Ampicillin resistance in enterococci was 19.6%. Eight isolates were vancomycin resistant and three isolates were teicoplanin resistant. Five <i>E. faecium</i> isolates were classified as MDR. This AGAR-Kids report highlights clear differences in the geographic distribution of pathogens and resistance profiles across Australia.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age of hepatitis B e antigen loss in Aboriginal, Torres Strait Islander and non-Indigenous residents of tropical Australia; implications for clinical care. 澳大利亚热带地区土著居民、托雷斯海峡岛民和非土著居民乙型肝炎 e 抗原丢失的年龄;对临床护理的影响。
Q3 Medicine Pub Date : 2024-08-21 DOI: 10.33321/cdi.2024.48.48
Liana Neldner, Sharna Radlof, Simon Smith, Margaret Littlejohn, Allison Hempenstall, Josh Hanson

Abstract: This study determined the hepatitis B e antigen (HBeAg) status of people living with chronic hepatitis B (CHB) in Far North Queensland (FNQ), Australia and their age of HBeAg loss. It was hoped that this would provide data to explain the stark difference in the incidence of hepatocellular carcinoma (HCC) between Aboriginal and Torres Strait Islander individuals living with CHB in FNQ, a finding that has been hypothesised to relate to differences in hepatitis B virus genotype. We identified every FNQ resident with CHB, determined their country of birth, their HBeAg status, the age they lost HBeAg and whether they identified as an Aboriginal, a Torres Strait Islander or a non-Indigenous individual. We then ascertained whether these demographic and virological variables were correlated. Of 1,474 individuals living with CHB in FNQ, 278 (19%) were Aboriginal, 507 (34%) were Torres Strait Islanders and 689 (47%) were non-Indigenous. Aboriginal individuals were less likely to be HBeAg positive (26/278, 9%) than Torres Strait Islander (91/507, 18%) and non-Indigenous (126/689, 18%) individuals, p < 0.0001. Aboriginal individuals lost HBeAg at an earlier age (median (interquartile range): 30 (23-39) years) than Torres Strait Islander (38 (29-49) years) and non-Indigenous (36 (29-47) years) individuals, p < 0.0001. Aboriginal individuals with CHB in FNQ are more likely to be HBeAg negative than Torres Strait Islander and non-Indigenous individuals and lose HBeAg at a younger age. This provides a biological basis for local clinicians' observation that Aboriginal individuals with CHB in FNQ are at a lower risk of HCC and data to support the principle of genotype-based care in the region.

摘要:本研究确定了澳大利亚远北昆士兰(FNQ)慢性乙型肝炎(CHB)患者的乙型肝炎 e 抗原(HBeAg)状态及其 HBeAg 消失的年龄。我们希望这能提供数据,解释远北昆士兰原住民和托雷斯海峡岛民慢性乙型肝炎患者之间肝细胞癌(HCC)发病率的巨大差异,这一发现被认为与乙型肝炎病毒基因型的差异有关。我们确定了每一位患有慢性乙型肝炎的原住民居民,确定了他们的出生国、HBeAg 状态、HBeAg 消失的年龄,以及他们是原住民、托雷斯海峡岛民还是非原住民。然后,我们确定了这些人口统计学变量和病毒学变量是否相关。在新南昆省的 1,474 名慢性阻塞性肺病患者中,278 人(19%)为原住民,507 人(34%)为托雷斯海峡岛民,689 人(47%)为非原住民。原住民的 HBeAg 阳性率(26/278,9%)低于托雷斯海峡岛民(91/507,18%)和非原住民(126/689,18%),P < 0.0001。原住民 HBeAg 阳性消失的年龄较早(中位数(四分位数间距):30(23-39)岁):与托雷斯海峡岛民(38(29-49)岁)和非土著居民(36(29-47)岁)相比,土著居民 30(23-39)岁就失去了 HBeAg,p < 0.0001。与托雷斯海峡岛民和非土著人相比,原住民 CHB 患者的 HBeAg 更有可能呈阴性,而且 HBeAg 阳性丧失的年龄更小。这为当地临床医生观察到原住民 CHB 患者罹患 HCC 的风险较低提供了生物学依据,也为该地区基于基因型的护理原则提供了数据支持。
{"title":"Age of hepatitis B e antigen loss in Aboriginal, Torres Strait Islander and non-Indigenous residents of tropical Australia; implications for clinical care.","authors":"Liana Neldner, Sharna Radlof, Simon Smith, Margaret Littlejohn, Allison Hempenstall, Josh Hanson","doi":"10.33321/cdi.2024.48.48","DOIUrl":"10.33321/cdi.2024.48.48","url":null,"abstract":"<p><strong>Abstract: </strong>This study determined the hepatitis B e antigen (HBeAg) status of people living with chronic hepatitis B (CHB) in Far North Queensland (FNQ), Australia and their age of HBeAg loss. It was hoped that this would provide data to explain the stark difference in the incidence of hepatocellular carcinoma (HCC) between Aboriginal and Torres Strait Islander individuals living with CHB in FNQ, a finding that has been hypothesised to relate to differences in hepatitis B virus genotype. We identified every FNQ resident with CHB, determined their country of birth, their HBeAg status, the age they lost HBeAg and whether they identified as an Aboriginal, a Torres Strait Islander or a non-Indigenous individual. We then ascertained whether these demographic and virological variables were correlated. Of 1,474 individuals living with CHB in FNQ, 278 (19%) were Aboriginal, 507 (34%) were Torres Strait Islanders and 689 (47%) were non-Indigenous. Aboriginal individuals were less likely to be HBeAg positive (26/278, 9%) than Torres Strait Islander (91/507, 18%) and non-Indigenous (126/689, 18%) individuals, <i>p</i> < 0.0001. Aboriginal individuals lost HBeAg at an earlier age (median (interquartile range): 30 (23-39) years) than Torres Strait Islander (38 (29-49) years) and non-Indigenous (36 (29-47) years) individuals, <i>p</i> < 0.0001. Aboriginal individuals with CHB in FNQ are more likely to be HBeAg negative than Torres Strait Islander and non-Indigenous individuals and lose HBeAg at a younger age. This provides a biological basis for local clinicians' observation that Aboriginal individuals with CHB in FNQ are at a lower risk of HCC and data to support the principle of genotype-based care in the region.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comorbidities and confusion: addressing COVID-19 vaccine access and information challenges. 合并症与混淆:应对 COVID-19 疫苗获取和信息方面的挑战。
Q3 Medicine Pub Date : 2024-08-21 DOI: 10.33321/cdi.2024.48.33
Katie Attwell, Leah Roberts, Christopher C Blyth

Objective: Early in the coronavirus disease 2019 (COVID-19) pandemic, evidence emerged that individuals with chronic and immunocompromising conditions faced increased risk of severe infection, including death. The Australian Government and public health authorities prioritised these citizens' access to vaccines, including them in phase 1b of the rollout from 22 March 2021. Given the rapidly evolving knowledge and advice, we sought to understand what people with comorbidities understood about their eligibility, where they obtained information, and their experiences interfacing with the program.

Methods: Through the mixed methods project Coronavax, we conducted semi-structured in-depth interviews with eight West Australians aged under 60 who signed up to the study's webpage and declared comorbidities pertinent to serious COVID-19 complications. Interviews were conducted during January-April 2022, audio-recorded, transcribed in full, and analysed in NVivo 20 using inductive methods. We validated participants' accounts of state government actions with a representative in person and in writing.

Results: We identified access and informational barriers - and a lack of understanding - about vaccine eligibility amongst West Australians with comorbidities. Amid a rapidly changing landscape of knowledge with subsequent policy implications, this group received insufficient information for their needs for understanding their place in the immunisation program.

Conclusions: Fast-changing knowledge about vaccines creates communication challenges for government and health professionals. We identify an urgent need to develop, pilot, and evaluate strategies for providing vaccination information in routine and pandemic settings.

目的:在 2019 年冠状病毒病(COVID-19)大流行初期,有证据表明患有慢性病和免疫力低下的人面临更高的严重感染风险,包括死亡。澳大利亚政府和公共卫生部门优先考虑让这些公民接种疫苗,从 2021 年 3 月 22 日起将他们纳入疫苗推广的 1b 阶段。鉴于知识和建议的快速发展,我们试图了解患有合并症的人对其资格的理解、他们从哪里获得信息以及他们与该计划的互动经历:通过 Coronavax 混合方法项目,我们对 8 名年龄在 60 岁以下的西澳大利亚人进行了半结构化深度访谈,这些人在研究网页上注册并申报了与 COVID-19 严重并发症相关的合并症。访谈于 2022 年 1 月至 4 月间进行,我们对访谈内容进行了录音和全文转录,并采用归纳法在 NVivo 20 中对访谈内容进行了分析。我们与一名代表当面和书面验证了参与者对州政府行为的描述:结果:我们发现西澳大利亚患有合并症的人在获得疫苗和信息方面存在障碍,而且对疫苗接种资格缺乏了解。在瞬息万变的知识环境以及随之而来的政策影响下,这一群体获得的信息不足以满足他们的需求,无法了解他们在免疫计划中的地位:结论:快速变化的疫苗知识给政府和医疗专业人员的沟通带来了挑战。我们发现,迫切需要制定、试验和评估在常规和大流行环境中提供疫苗接种信息的策略。
{"title":"Comorbidities and confusion: addressing COVID-19 vaccine access and information challenges.","authors":"Katie Attwell, Leah Roberts, Christopher C Blyth","doi":"10.33321/cdi.2024.48.33","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.33","url":null,"abstract":"<p><strong>Objective: </strong>Early in the coronavirus disease 2019 (COVID-19) pandemic, evidence emerged that individuals with chronic and immunocompromising conditions faced increased risk of severe infection, including death. The Australian Government and public health authorities prioritised these citizens' access to vaccines, including them in phase 1b of the rollout from 22 March 2021. Given the rapidly evolving knowledge and advice, we sought to understand what people with comorbidities understood about their eligibility, where they obtained information, and their experiences interfacing with the program.</p><p><strong>Methods: </strong>Through the mixed methods project Coronavax, we conducted semi-structured in-depth interviews with eight West Australians aged under 60 who signed up to the study's webpage and declared comorbidities pertinent to serious COVID-19 complications. Interviews were conducted during January-April 2022, audio-recorded, transcribed in full, and analysed in NVivo 20 using inductive methods. We validated participants' accounts of state government actions with a representative in person and in writing.</p><p><strong>Results: </strong>We identified access and informational barriers - and a lack of understanding - about vaccine eligibility amongst West Australians with comorbidities. Amid a rapidly changing landscape of knowledge with subsequent policy implications, this group received insufficient information for their needs for understanding their place in the immunisation program.</p><p><strong>Conclusions: </strong>Fast-changing knowledge about vaccines creates communication challenges for government and health professionals. We identify an urgent need to develop, pilot, and evaluate strategies for providing vaccination information in routine and pandemic settings.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Respiratory diphtheria in the time of Omicron. 奥米克隆时代的呼吸道白喉。
Q3 Medicine Pub Date : 2024-08-21 DOI: 10.33321/cdi.2024.48.41
Annabeth Simpson, Paul Douglas, Jenny Draper, Vitali Sintchenko, Zoe Cutcher, Daniel Ashton

Abstract: Diphtheria is a potentially fatal bacterial infection caused by toxin-producing strains of corynebacteria, most often Corynebacterium diphtheriae and less commonly Corynebacterium ulcerans. Incidence of the disease has fallen significantly since the introduction of vaccination programs; it is now rare in countries with high vaccination coverage such as Australia. This article presents the most recent respiratory cases of diphtheria in two children in New South Wales-the first locally acquired childhood cases in Australia in 30 years-and discusses potential contributing factors. These encompass the lack of clinical awareness and the delays in laboratory diagnosis in regional laboratories. The cases also highlight the problem of vaccine hesitancy and the role that primary carers play in addressing these anxieties. While clinical management of the cases progressed well, factors in the public health responses were complicated by access to appropriate care and by delays in antibiotic sensitivity profiles. The public health response to these cases raises important considerations for clinicians and public health practitioners, including preparedness for rare and re-emerging diseases, the need for culturally safe environments and the importance of addressing vaccine hesitancy. Preparedness requires consideration of the capacity of regional health systems with fewer resources and of how public health departments can support response to multiple crises. Preparedness also relies on access to necessary diagnostic laboratory resources, on up-to-date guidelines, and on maintaining awareness among clinicians for these rare infections.

摘要:白喉是一种可能致命的细菌感染,由产生毒素的棒状杆菌菌株引起,最常见的是白喉棒状杆菌,较少见的是溃疡棒状杆菌。自引入疫苗接种计划以来,该病的发病率已大幅下降;目前在澳大利亚等疫苗接种覆盖率较高的国家已很少见。本文介绍了最近在新南威尔士州两名儿童中出现的白喉呼吸道病例--这是澳大利亚30年来首次在当地出现的儿童病例--并讨论了潜在的诱因。这些因素包括临床意识的缺乏和地区实验室诊断的延误。这些病例还突显了疫苗接种犹豫不决的问题,以及初级护理人员在解决这些焦虑方面所起的作用。虽然这些病例的临床治疗进展顺利,但公共卫生应对措施却因获得适当治疗的途径和抗生素敏感性分析的延误而变得复杂。针对这些病例的公共卫生应对措施为临床医生和公共卫生从业人员提出了重要的考虑因素,包括对罕见疾病和再发疾病的防备、文化安全环境的需要以及解决疫苗犹豫不决问题的重要性。做好准备需要考虑资源较少的地区卫生系统的能力,以及公共卫生部门如何支持应对多重危机。准备工作还有赖于获得必要的实验室诊断资源、最新的指导方针以及保持临床医生对这些罕见感染的认识。
{"title":"Respiratory diphtheria in the time of Omicron.","authors":"Annabeth Simpson, Paul Douglas, Jenny Draper, Vitali Sintchenko, Zoe Cutcher, Daniel Ashton","doi":"10.33321/cdi.2024.48.41","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.41","url":null,"abstract":"<p><strong>Abstract: </strong>Diphtheria is a potentially fatal bacterial infection caused by toxin-producing strains of corynebacteria, most often <i>Corynebacterium diphtheriae</i> and less commonly <i>Corynebacterium ulcerans</i>. Incidence of the disease has fallen significantly since the introduction of vaccination programs; it is now rare in countries with high vaccination coverage such as Australia. This article presents the most recent respiratory cases of diphtheria in two children in New South Wales-the first locally acquired childhood cases in Australia in 30 years-and discusses potential contributing factors. These encompass the lack of clinical awareness and the delays in laboratory diagnosis in regional laboratories. The cases also highlight the problem of vaccine hesitancy and the role that primary carers play in addressing these anxieties. While clinical management of the cases progressed well, factors in the public health responses were complicated by access to appropriate care and by delays in antibiotic sensitivity profiles. The public health response to these cases raises important considerations for clinicians and public health practitioners, including preparedness for rare and re-emerging diseases, the need for culturally safe environments and the importance of addressing vaccine hesitancy. Preparedness requires consideration of the capacity of regional health systems with fewer resources and of how public health departments can support response to multiple crises. Preparedness also relies on access to necessary diagnostic laboratory resources, on up-to-date guidelines, and on maintaining awareness among clinicians for these rare infections.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outbreak investigation of norovirus gastroenteritis in a childcare facility in Central Queensland, Australia: a household level case series analysis. 澳大利亚昆士兰州中部一家托儿所诺如病毒肠胃炎疫情调查:家庭病例系列分析。
Q3 Medicine Pub Date : 2024-08-21 DOI: 10.33321/cdi.2024.48.46
Connie Schulz, Amanda Wyatt, Jacina Walker, Nicolas Smoll, Emma Field, Gulam Khandaker

Introduction: Noroviruses are one of the most common causes of gastroenteritis in all age groups, including children. However, little has been reported on the transmission of norovirus within childcare facilities and the subsequent impact at the household level.

Methods: We conducted an outbreak investigation of norovirus gastroenteritis in Central Queensland, Australia during May 2021, in a childcare facility and the associated exposed households. Case definitions and outbreak management were employed as per the Communicable Disease Network Australia guidelines for norovirus and suspected viral gastroenteritis. Each case or carer and respective household member was interviewed to determine the date and time of symptom onset, health outcomes, and infector-infectee pairs. We estimated attack rates within the childcare facility and households, and basic reproductive number (R0) for norovirus using time-dependent methods.

Results: A total of 41 people developed gastrointestinal symptoms as a result of this outbreak, with 25 cases (61%) acquiring the infection in the centre and 16 cases (39%) occurring at households. Serial intervals were estimated as a mean 2.4 days (standard deviation 1.7 days), with a majority of cases (73%) in children under two years of age within the centre. Three faecal specimens were obtained, all detecting norovirus genotype II. The time-dependent R0 was 1.5 (95% confidence interval [95% CI]: 1.0-2.2).

Discussion: The attack rate within the childcare facility was highest amongst children aged less than 2 years, highlighting the risk of infection for this age group. We recommend the exclusion of asymptomatic household contacts from childcare facilities to reduce the length and severity of norovirus outbreaks. Further investigation into childcare facility risk factors and associated households are required to optimise public health interventions.

导言:诺如病毒是包括儿童在内的所有年龄组人群中最常见的肠胃炎病因之一。然而,关于诺如病毒在托儿所内的传播及其对家庭的影响却鲜有报道:方法:2021 年 5 月,我们在澳大利亚昆士兰州中部的一家托儿所和相关暴露家庭中开展了诺如病毒肠胃炎疫情调查。病例定义和疫情管理按照澳大利亚传染病网络诺如病毒和疑似病毒性肠胃炎指南进行。我们对每个病例或照护者以及相关家庭成员进行了访谈,以确定症状出现的日期和时间、健康状况以及感染者与被感染者之间的关系。我们采用时间依赖法估算了托儿所和家庭内的发病率以及诺如病毒的基本繁殖数(R0):结果:共有 41 人因疫情而出现胃肠道症状,其中 25 例(61%)在托儿所感染,16 例(39%)在家庭感染。据估计,感染间隔平均为 2.4 天(标准差为 1.7 天),大多数病例(73%)发生在中心内两岁以下的儿童身上。共采集了三份粪便标本,均检测出诺如病毒基因 II 型。与时间相关的R0为1.5(95%置信区间[95% CI]:1.0-2.2):讨论:两岁以下儿童在托儿所内的发病率最高,凸显了这一年龄组的感染风险。我们建议将无症状的家庭接触者排除在托儿所之外,以减少诺如病毒爆发的持续时间和严重程度。为了优化公共卫生干预措施,需要进一步调查托儿所的风险因素和相关家庭。
{"title":"Outbreak investigation of norovirus gastroenteritis in a childcare facility in Central Queensland, Australia: a household level case series analysis.","authors":"Connie Schulz, Amanda Wyatt, Jacina Walker, Nicolas Smoll, Emma Field, Gulam Khandaker","doi":"10.33321/cdi.2024.48.46","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.46","url":null,"abstract":"<p><strong>Introduction: </strong>Noroviruses are one of the most common causes of gastroenteritis in all age groups, including children. However, little has been reported on the transmission of norovirus within childcare facilities and the subsequent impact at the household level.</p><p><strong>Methods: </strong>We conducted an outbreak investigation of norovirus gastroenteritis in Central Queensland, Australia during May 2021, in a childcare facility and the associated exposed households. Case definitions and outbreak management were employed as per the Communicable Disease Network Australia guidelines for norovirus and suspected viral gastroenteritis. Each case or carer and respective household member was interviewed to determine the date and time of symptom onset, health outcomes, and infector-infectee pairs. We estimated attack rates within the childcare facility and households, and basic reproductive number (R0) for norovirus using time-dependent methods.</p><p><strong>Results: </strong>A total of 41 people developed gastrointestinal symptoms as a result of this outbreak, with 25 cases (61%) acquiring the infection in the centre and 16 cases (39%) occurring at households. Serial intervals were estimated as a mean 2.4 days (standard deviation 1.7 days), with a majority of cases (73%) in children under two years of age within the centre. Three faecal specimens were obtained, all detecting norovirus genotype II. The time-dependent R<sub>0</sub> was 1.5 (95% confidence interval [95% CI]: 1.0-2.2).</p><p><strong>Discussion: </strong>The attack rate within the childcare facility was highest amongst children aged less than 2 years, highlighting the risk of infection for this age group. We recommend the exclusion of asymptomatic household contacts from childcare facilities to reduce the length and severity of norovirus outbreaks. Further investigation into childcare facility risk factors and associated households are required to optimise public health interventions.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study. 澳大利亚维多利亚州按年龄和疫苗接种状况划分的 COVID-19 病例确定率差异:血清监测和记录关联研究。
Q3 Medicine Pub Date : 2024-08-21 DOI: 10.33321/cdi.2024.48.28
Joshua Szanyi, David J Price, Kylie S Carville, Mitch Batty, Sarah Yallop, Suellen Nicholson, Theo Karapanagiotidis, Stacey Rowe, Sheena Sullivan, Vinay Menon, Daniel West, Lakshmi Manoharan, Eliza Copsey, Suman S Majumdar, Brett Sutton, Deborah A Williamson, Jodie McVernon

Objectives: To compare serological evidence of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with linked coronavirus disease 2019 (COVID-19) case notification data in Victoria, Australia, and to determine in vitro SARS-CoV-2 neutralisation activity based on prior infection and vaccination history.

Design, setting, participants: Four cross-sectional serological surveys were conducted between 30 June and 31 October 2022 (a period of Omicron BA.4/BA.5 dominance) using 1,974 residual serum samples obtained from the Victorian Infectious Diseases Reference Laboratory. Serological results were linked to COVID-19 case notification and vaccination data. Surrogate virus neutralisation testing was performed to obtain in vitro inhibition estimates by anti-nucleocapsid serostatus and COVID-19 vaccination history.

Main outcome measures: Adjusted anti-SARS-CoV-2 spike and nucleocapsid seropositivity by sex, age and region of residence; adjusted proportion of cases notified by anti-nucleocapsid serostatus, age and number of COVID-19 vaccination doses received; adjusted percentage in vitro inhibition against wildtype and Omicron BA.4/BA.5 SARS-CoV-2 variants by anti-nucleocapsid serostatus and COVID-19 vaccination history.

Results: The prevalence of anti-SARS-CoV-2 nucleocapsid antibodies was inversely proportional to age. In October 2022, prevalence was 84% (95% confidence interval [95% CI]: 75-93%) among 18-29-year-olds, compared to 39% (95% CI: 27-52%) among ≥ 80-year-olds. In most age groups, approximately 40% of COVID-19 cases appear to have been notified via existing surveillance mechanisms. Case notification was highest among individuals older than 80 years and people who had received COVID-19 vaccine booster doses. In vitro neutralisation of Omicron BA.4/BA.5 sub-variants was highest for individuals with evidence of both prior infection and booster vaccination.

Conclusions: Under-notification of SARS-CoV-2 infections in the Victorian population is not uniform across age and vaccination strata. Seroprevalence data that give insights into case notification behaviour provide additional context for the interpretation of existing COVID-19 surveillance information.

目的比较澳大利亚维多利亚州严重急性呼吸系统综合征冠状病毒2(SARS-CoV-2)既往感染的血清学证据与2019年冠状病毒疾病(COVID-19)病例通报数据,并根据既往感染和疫苗接种史确定体外SARS-CoV-2中和活性:在 2022 年 6 月 30 日至 10 月 31 日期间(Omicron BA.4/BA.5 优势期),利用从维多利亚传染病参考实验室获得的 1,974 份残留血清样本进行了四次横断面血清学调查。血清学结果与 COVID-19 病例通报和疫苗接种数据相关联。进行替代病毒中和试验,以获得抗核头壳血清状态和 COVID-19 疫苗接种史的体外抑制估算值:按性别、年龄和居住地区调整的抗 SARS-CoV-2 穗状病毒和核头状病毒血清阳性率;按抗核头状病毒血清状态、年龄和接种 COVID-19 疫苗的剂量调整的病例通报比例;按抗核头状病毒血清状态和 COVID-19 疫苗接种史调整的对野生型和 Omicron BA.4/BA.5 SARS-CoV-2 变体的体外抑制百分比:结果:抗SARS-CoV-2核头抗体的流行率与年龄成反比。2022 年 10 月,18-29 岁人群的感染率为 84%(95% 置信区间 [95%CI]:75-93%),而≥80 岁人群的感染率为 39%(95% CI:27-52%)。在大多数年龄组中,约 40% 的 COVID-19 病例似乎是通过现有监测机制通报的。病例通报率最高的人群是 80 岁以上的老人和接种过 COVID-19 疫苗加强剂的人。体外中和 Omicron BA.4/BA.5 亚变异体的比例在有证据表明曾感染和接种过加强疫苗的人群中最高:结论:维多利亚州人口中 SARS-CoV-2 感染的通知不足现象在不同年龄和接种疫苗的阶层中并不一致。血清流行率数据有助于深入了解病例通报行为,为解读现有的 COVID-19 监测信息提供了更多的背景资料。
{"title":"Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study.","authors":"Joshua Szanyi, David J Price, Kylie S Carville, Mitch Batty, Sarah Yallop, Suellen Nicholson, Theo Karapanagiotidis, Stacey Rowe, Sheena Sullivan, Vinay Menon, Daniel West, Lakshmi Manoharan, Eliza Copsey, Suman S Majumdar, Brett Sutton, Deborah A Williamson, Jodie McVernon","doi":"10.33321/cdi.2024.48.28","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.28","url":null,"abstract":"<p><strong>Objectives: </strong>To compare serological evidence of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with linked coronavirus disease 2019 (COVID-19) case notification data in Victoria, Australia, and to determine <i>in vitro</i> SARS-CoV-2 neutralisation activity based on prior infection and vaccination history.</p><p><strong>Design, setting, participants: </strong>Four cross-sectional serological surveys were conducted between 30 June and 31 October 2022 (a period of Omicron BA.4/BA.5 dominance) using 1,974 residual serum samples obtained from the Victorian Infectious Diseases Reference Laboratory. Serological results were linked to COVID-19 case notification and vaccination data. Surrogate virus neutralisation testing was performed to obtain <i>in vitro</i> inhibition estimates by anti-nucleocapsid serostatus and COVID-19 vaccination history.</p><p><strong>Main outcome measures: </strong>Adjusted anti-SARS-CoV-2 spike and nucleocapsid seropositivity by sex, age and region of residence; adjusted proportion of cases notified by anti-nucleocapsid serostatus, age and number of COVID-19 vaccination doses received; adjusted percentage <i>in vitro</i> inhibition against wildtype and Omicron BA.4/BA.5 SARS-CoV-2 variants by anti-nucleocapsid serostatus and COVID-19 vaccination history.</p><p><strong>Results: </strong>The prevalence of anti-SARS-CoV-2 nucleocapsid antibodies was inversely proportional to age. In October 2022, prevalence was 84% (95% confidence interval [95% CI]: 75-93%) among 18-29-year-olds, compared to 39% (95% CI: 27-52%) among ≥ 80-year-olds. In most age groups, approximately 40% of COVID-19 cases appear to have been notified via existing surveillance mechanisms. Case notification was highest among individuals older than 80 years and people who had received COVID-19 vaccine booster doses. <i>In vitro</i> neutralisation of Omicron BA.4/BA.5 sub-variants was highest for individuals with evidence of both prior infection and booster vaccination.</p><p><strong>Conclusions: </strong>Under-notification of SARS-CoV-2 infections in the Victorian population is not uniform across age and vaccination strata. Seroprevalence data that give insights into case notification behaviour provide additional context for the interpretation of existing COVID-19 surveillance information.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Yersiniosis outbreaks in Gold Coast residential aged care facilities linked to nutritionally-supplemented milkshakes, January-April 2023. 黄金海岸养老院爆发的耶尔森氏菌病与营养补充奶昔有关,2023年1月至4月。
Q3 Medicine Pub Date : 2024-08-21 DOI: 10.33321/cdi.2024.48.30
Candice Colbran, Fiona May, Kate Alexander, Ian Hunter, Russell Stafford, Robert Bell, Anne Cowdry, Fiona Vosti, Sharon Jurd, Trudy Graham, Gino Micalizzi, Rikki Graham, Vicki Slinko

Abstract: In January 2023, an outbreak of Yersinia enterocolitica in residential aged care facilities (RACF) was identified by the Gold Coast Public Health Unit and confirmed using whole genome sequencing. During the outbreak period there were 11 confirmed and 14 probable cases of Y. enterocolitica notified in RACF and 30 suspected cases with compatible illness. Eleven cases (20%) were confirmed as Biotype 1A non-typable (BT1A NT) sequence type (ST) 278 within 4-15 single nucleotide polymorphisms (SNP) of each other. Combined epidemiological, trace-back and laboratory investigations identified nutritional milkshakes, stored at ideal growing conditions for Yersinia and given to vulnerable RACF residents, as the likely outbreak vehicle. This highlights that Y. enterocolitica Biotype 1A can be pathogenic in humans and transmission via atypical sources should be considered in outbreak investigations. This report outlines the response and challenges associated with investigating outbreaks in aged care.

摘要:2023 年 1 月,黄金海岸公共卫生单位(Gold Coast Public Health Unit)发现养老院(RACF)爆发了小肠结肠炎耶尔森菌疫情,并通过全基因组测序进行了确认。在疫情爆发期间,安老院共通报了 11 例确诊病例和 14 例疑似小肠结肠炎耶尔森菌病例,以及 30 例疑似病例。有 11 个病例(20%)被证实为生物型 1A 不可分型(BT1A NT)序列类型(ST)278,相互之间的单核苷酸多态性(SNP)相差 4-15 个。综合流行病学、溯源和实验室调查,确定营养奶昔可能是疫情爆发的媒介,营养奶昔储存在耶尔森氏菌理想的生长条件下,并提供给易感染的 RACF 居民。这突出表明,小肠结肠炎耶尔森菌生物型 1A 对人类具有致病性,在疫情调查中应考虑到通过非典型来源的传播。本报告概述了与调查养老院疫情相关的应对措施和挑战。
{"title":"Yersiniosis outbreaks in Gold Coast residential aged care facilities linked to nutritionally-supplemented milkshakes, January-April 2023.","authors":"Candice Colbran, Fiona May, Kate Alexander, Ian Hunter, Russell Stafford, Robert Bell, Anne Cowdry, Fiona Vosti, Sharon Jurd, Trudy Graham, Gino Micalizzi, Rikki Graham, Vicki Slinko","doi":"10.33321/cdi.2024.48.30","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.30","url":null,"abstract":"<p><strong>Abstract: </strong>In January 2023, an outbreak of <i>Yersinia enterocolitica</i> in residential aged care facilities (RACF) was identified by the Gold Coast Public Health Unit and confirmed using whole genome sequencing. During the outbreak period there were 11 confirmed and 14 probable cases of <i>Y. enterocolitica</i> notified in RACF and 30 suspected cases with compatible illness. Eleven cases (20%) were confirmed as Biotype 1A non-typable (BT1A NT) sequence type (ST) 278 within 4-15 single nucleotide polymorphisms (SNP) of each other. Combined epidemiological, trace-back and laboratory investigations identified nutritional milkshakes, stored at ideal growing conditions for <i>Yersinia</i> and given to vulnerable RACF residents, as the likely outbreak vehicle. This highlights that <i>Y. enterocolitica</i> Biotype 1A can be pathogenic in humans and transmission via atypical sources should be considered in outbreak investigations. This report outlines the response and challenges associated with investigating outbreaks in aged care.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Communicable diseases intelligence (2018)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1